tbuckley/cabot-search huggingface dataset:
Laboratory animal allergy is preventable in modern research facilities
Authors: Johanna R. Feary, Susan J. Schofield, Jennifer Canizales, Bernadette Fitzgerald, James Potts, Meinir Jones, Paul Cullinan
Journal: European Respiratory Journal (2019)

Historical data suggest 15% of laboratory animal workers develop IgE sensitisation and 10% symptoms of laboratory animal allergy (LAA), including occupational asthma. Individually ventilated cages (IVCs) are replacing conventional open cages; we sought to evaluate their impact on the development of LAA.We surveyed 750 laboratory animal workers and measured airborne Mus m 1 (mouse allergen) levels in seven UK institutions. We compared the prevalence of sensitisation to mouse proteins (by specific IgE assay or skin prick test) and of work-related allergic symptoms in IVC-only and open cage units.Full-shift Mus m 1 levels were lower in IVC than open cage units (geometric mean 1.00 (95% CI 0.73-1.36) versus 8.35 (95% CI 6.97-9.95) ng·m-3; p<0.001), but varied eight-fold across the IVC units (geometric mean range 0.33-4.12 ng·m-3). Primary analyses on data from 216 participants with ≤3 years exposure to mice revealed a lower prevalence of sensitisation in those working in IVC units compared with conventional cage units (2.4% (n=2) versus 9.8% (n=13); p=0.052). Sensitisation in IVC units varied from 0% to 12.5%; the use of fitted respiratory protection was less common in IVC units where prevalence of sensitisation was higher. Work-related allergy symptoms were more frequently reported by mouse-sensitised individuals (46.7% versus 10.9%; p<0.001) and only by those working in open cage units.In contemporary practice, LAA is now largely preventable with the use of IVC systems and the judicious use of appropriate respiratory protection.
Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline
Authors: Christopher Lieu, Erin B. Kennedy, Emily Bergsland, Jordan Berlin, Thomas J. George, Sharlene Gill, Philip J. Gold, Alex Hantel, Lee Jones, Najjia Mahmoud, Jeffrey Meyerhardt, Arden M. Morris, Erika Ruíz-García, Y. Nancy You, Nancy Baxter
Journal: Journal of Clinical Oncology (2019)

To develop recommendations for duration of adjuvant chemotherapy with a fluoropyrimidine and oxaliplatin for patients with completely resected stage III colon cancer based on the results of trials of 3 months compared with 6 months of treatment.ASCO convened an Expert Panel and conducted a systematic review of relevant studies. The guideline recommendations were based on the review of evidence by the Expert Panel.Pooled data from the six International Duration Evaluation of Adjuvant Chemotherapy (IDEA) Collaboration randomized controlled trials comprise the evidence base for these guideline recommendations.The recommendations for therapy duration apply to patients with completely resected stage III colon cancer who are being offered adjuvant chemotherapy with oxaliplatin and a fluoropyrimidine. Recommendations are informed by the findings of a recent pooled analysis of clinical trials that compared 6 months versus 3 months of oxaliplatin-based chemotherapy. For patients at a high risk of recurrence (T4 and/or N2), adjuvant chemotherapy should be offered for a duration of 6 months. For patients at a low risk of recurrence (T1, T2, or T3 and N1), either 6 months of adjuvant chemotherapy or a shorter duration of 3 months may be offered on the basis of a potential reduction in adverse events and no significant difference in disease-free survival with the 3-month regimen. In determining duration of therapy, the Expert Panel recommends a shared decision-making approach, taking into account patient characteristics, values and preferences, and other factors and including a discussion of the potential for benefit and risks of harm associated with treatment duration. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .
PS-083-Serum albumin concentration as guide for long-term albumin treatment in patients with cirrhosis and uncomplicated ascites: Lessons from the ANSWER study
Authors: Paolo Caraceni, Oliviero Riggio, Paolo Angeli, Carlo Alessandria, Sergio Neri, Francesco Giuseppe Foschi, Fabio Levantesi, Aldo Airoldi, Loredana Simone, Gianluca Svegiati-Baroni, Stefano Fagiuoli, Roberto Giulio Romanelli, Raffaele Cozzolongo, Vito Di Marco, Vincenzo Sangiovanni, Filomena Morisco, Pierluigi Toniutto, Annalisa Tortora, Rosanna De Marco, Silvia Nardelli, Salvatore Piano, Chiara Elia, Andrea Roncadori, Manuel Tufoni, Giacomo Zaccherini, Mauro Bernardi
Journal: Journal of Hepatology (2019)
TCTAP A-023 Large-diameter Coronary Artery Stenting
Authors: Sergey Vladimirovich Sokolov, Irina E. Nikolaeva, Vladimir V. Plechev, Bogdan Aleksandrovich Oleynik, Igor Vyacheslavovich Dmitriev, Igor V. Buzaev
Journal: Journal of the American College of Cardiology (2019)
TCTAP A-010 Long-term Outcomes After Left Main Coronary Artery Percutaneous Coronary Intervention in Patients Presenting with Acute Coronary Syndrome
Authors: Sida Jia, Na Xu, Yi Yao, Yuejin Yang, Bo Xu, Runlin Gao, Jinqing Yuan
Journal: Journal of the American College of Cardiology (2019)
THU-113-Comparison between safety and efficacy of two treatment regimens for pediatric patients with chronic hepatitis C virus: Sofosbuvir/ledipasvir versus sofosbuvir/daclatasvir regimen
Authors: Mohamed Ahmed, Abdelfattah Hanno, Soraya Hamouda, Manal Abdelgawad, Hossam Abouelkhier
Journal: Journal of Hepatology (2019)
The Patient Needs in Asthma Treatment (NEAT) questionnaire: Further evidence on its psychometric properties
Authors: Julia Schreitmüller, Christian Apfelbacher, Aziz Sheikh, Adrian Loerbroks
Journal: Allergy (2019)

Abstract Background Building on previous psychometric work, we sought to assess the Patient Needs in Asthma Treatment (NEAT) questionnaire's validity, responsiveness to change, and the minimal important change (MIC) over a 3‐year period (Study 1) and its reliability and the smallest detectable change (SDC) in a test‐retest study (Study 2) among patients self‐reporting physician‐diagnosed asthma. Methods In Study 1, a total of 207 patients completed a survey which included the NEAT, the Asthma Control Test (ACT), the Asthma Quality of Life Questionnaire‐Sydney (AQLQ‐S), and a question on treatment satisfaction in 2014 and 2017. In Study 2, a total of 78 patients completed NEAT twice on average four weeks apart in 2018. Results Concurrent validity: In linear regressions, unmet patient needs were cross‐sectionally associated with poorer asthma control (β = −0.21; P = 0.01), asthma‐related quality of life (QoL) (β = 0.31; P &lt; 0.01), and treatment satisfaction (β = −0.59; P &lt; 0.01). Predictive Validity: Higher unmet needs at baseline predicted worse treatment satisfaction at follow‐up (β = −0.28; P &lt; 0.01), but neither asthma control nor asthma‐related QoL. Responsiveness to change was demonstrated by linear regressions of changes in the total NEAT score and changes in AQLQ‐S (β = 0.21; P &lt; 0.01) and treatment satisfaction (β = −0.36; P &lt; 0.01). MIC: Patients whose NEAT score increased between baseline and follow‐up by the identified MIC (0.301) reported lower treatment satisfaction at follow‐up (β = −0.17; P = 0.01). Test‐retest reliability was demonstrated by correlations between NEAT baseline and follow‐up scores (eg, intra‐class correlation coefficients for total score = 0.78). The SDC (0.384) was slightly larger than MIC. Conclusion NEAT is a promising tool for assessing asthma treatment needs.
THU-457-DoubleCortin/Like Kinase 1 (DCLK1) expression characterized specific cancer stem cell subpopulations of human cholangiocarcinoma primary cell cultures where its inhibition exerts anti-neoplastic effects
Authors: Sabina Di Matteo, Lorenzo Nevi, Vincenzo Cardinale, llaria Grazia Zizzari, Valeria Ambrosino, Francesca Biancaniello, Daniele Costantini, Samira Safarikia, Valerio De Peppo, Agostino Maria De Rose, Fabio Melandro, Mariaconsiglia Bragazzi, Felice Giuliante, Pasquale B. Berloco, Gianluca Grazzi, Guido Carpino, Eugenio Gaudio, Domenico Alvaro
Journal: Journal of Hepatology (2019)
SAT-004-Bacterial translocation in patients with liver cirrhosis and variceal bleeding
Authors: Ioanna Aggeletopoulou, Maria Kalafateli, Demetrious Samonakis, D. Goukos, panagiota spantidea, Georgios Tsiaousis, Aikaterini Mantaka, Maria Rodi, Katerina Karaivazoglou, Hariklia Kranidioti, Stylianos Asimakopoulos, Spilios Manolakopoulos, George Daikos, Charalampos Gogos, Athanasia Mouzaki, Konstantinos Thomopoulos, Christos Triantos
Journal: Journal of Hepatology (2019)
FRI-159-Can HBcrAg and pre-genomic HBV RNA predict the risk of ALT flares after nucleoside analogue therapy withdrawal: delineating the clinical utility of new biomarkers?
Authors: Ivana Carey, Jeffrey Gersch, Matthew Bruce, Bo Wang, Mary Kuhns, Gavin Cloherty, Geoffrey Dusheiko, Kosh Agarwal
Journal: Journal of Hepatology (2019)
THU-251-Metabolic risk factors for advanced liver disease among alcohol risk users in the general population
Authors: Fredrik Åberg, Pauli Puukka, Perttu Sahlman, Markku Nissinen, Veikko Salomaa, Satu Männistö, Annamari Lundqvist, Markus Perola, Antti Jula, Martti Färkkilä
Journal: Journal of Hepatology (2019)
SAT-497-Individual surveillance using PAGE-B score-based hepatocellular carcinoma risk in chronic hepatitis B patients under potent antiviral therapy
Authors: Minjong Lee, Ji Hyun Kim, Seong Hee Kang, Tae Suk Kim, Baek Gyu Jun, Ki Tae Suk, Moon Young Kim, Young Don Kim, Gab Jin Cheon, Soon Koo Baik, Dong Joon Kim, Dae Hee Choi
Journal: Journal of Hepatology (2019)
Resurgence in Diabetes-Related Complications
Authors: Edward W. Gregg, Israel Hora, Stephen R. Benoit
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Combined sunitinib and IMRT for preoperative treatment of locally advanced soft tissue sarcoma: Results of a phase I trial of the German Interdisciplinary Sarcoma Group GISG 03.
Authors: Jens Jakob, Anna Simeonova, Bernd Kasper, Ulrich Ronellenfitsch, Geraldine Rauch, Frederik K. Wenz, Peter Hohenberger
Journal: Journal of Clinical Oncology (2015)

10541 Background: Experimental data indicate that concurrent treatment with anti-angiogenic substances such as sunitinib improves the efficacy of irradiation. The aim of this phase I trial was to establish the safety profile and recommended dose of sunitinib combined with irradiation as preoperative treatment for soft tissue sarcomas. Methods: Patients with locally advanced, non-metastatic soft tissue sarcomas received sunitinib (orally, continuous dosing, 3+3 study design, dose level 1: 25 mg, dose level 2: 37.5 mg, NCT01498835) two weeks prior and during preoperative intensity modulated radiation therapy (25 x 1.8 Gy for retroperitoneal tumors, 28 x 1.8 Gy for extremity tumors). Surgery was performed 5 to 8 weeks after neoadjuvant treatment. Primary endpoint was the recommended dose for subsequent trials. Toxicity was scored according to CTCAE 4.0 criteria. Secondary endpoints were postoperative morbidity and treatment response. Results: Nine patients with a median age of 52 years were enrolled in dose level 1 (6/9) and 2 (3/9). Median tumor size was 11 cm. Tumors were located in the retroperitoneum (4/9), lower leg (3/9) or trunk (2/9). Most frequent toxicities of any grade were hematological (8/9), skin (6/9) and oral (5/9) toxicity. At dose level 1, 1/6 patients developed dose limiting grade 4 lymphopenia but recovered completely after discontinuation of sunitinib. At dose level 2, 0/3 patients developed dose limiting toxicity. 5/9 patients required dose adjustments due to toxicity. Skin toxicity within the radiation field did not exceed grade 2. All patients underwent tumor resection (8/9 R0 and 1/9 R1). 2/9 patients had postoperative complications requiring re-intervention. Treatment response according to RECIST was as follows: partial response 1/9, stable disease 7/9, progressive disease 1/9. Pathological examination revealed ≥ 95% tumor necrosis in 3/9 resected specimens. Conclusions: Combined preoperative treatment of extremity and retroperitoneal soft tissue sarcoma with irradiation and sunitinib is tolerable and warrants further investigation. The recommended dose of sunitinib for further testing is 37.5 mg. Clinical trial information: NCT01498835.
LBP-06-High Seroprotection Rates Achieved with Two Doses of Sci-B-Vac, a Third Generation Hepatitis B containing PreS, PreS2 and S Antigens.
Authors: Francisco Diaz-Mitoma, Johanna Spaans, Nathalie Machluf, David Anderson, Avi Mazaltov
Journal: Journal of Hepatology (2019)
Abstract 16624: Lung Cancer Screening With CT, Coronary Artery Calcification and Cardiovascular Events
Authors: Michael T Lu, Oyere K Onuma, Joseph M Massaro, Ralph B D’Agostino, Christopher J O’Donnell, Udo Hoffmann
Journal: Circulation (2015)

Background: The Centers for Medicare &amp; Medicaid Services (CMS) recently approved lung cancer screening with CT. It is unclear whether reporting coronary artery calcium (CAC) on lung screening CT could improve identification of adults at risk for cardiovascular events (CVD) and competing risk from lung cancer. Thus we determined the incidence of hard CVD (myocardial infarction, stroke or coronary/cerebrovascular death), lung cancer (diagnosis or death) and CAC in adults eligible and ineligible for lung cancer screening. Methods: This longitudinal community-based cohort study included Framingham Heart Study Offspring Cohort participant-exams age 55-77 and free of prevalent cardiovascular disease and lung cancer from exams 3 (1984 – 1987) and 7 (1998 – 2001). Participants were divided into screening eligible and ineligible groups by CMS criteria (current or recent (≤15 years) former smokers with ≥30 pack-year history). Multivariate-adjusted cox proportional hazards models assessed the effect of screening eligibility on incident hard CVD and incident lung cancer. In participants who had CAC CT at exam 7, cross-sectional association between screening eligibility, high CAC score &gt;300 and incident CVD was assessed. Raw incidence rates are reported; p values are adjusted for age, sex and traditional risk factors aside from smoking. Results: Of 3085 participant-exams 20% were eligible for lung cancer screening. In mean follow up of 9.9 years, there were 281 incident CVD and 69 lung cancer events. In both groups, incident CVD was more frequent than lung cancer (eligible: 13% vs 7%, p=0.002; ineligible: 8% vs 1%, p&lt;0.001). The screening eligible had more incident CVD (13% vs 8%, p&lt;0.001) and lung cancer (7% vs 1%, p&lt;0.001) than the ineligible. CAC CT was available in 107 screening eligible and 667 ineligible participants; CAC &gt;300 was more common in the screening eligible (33% vs 23%, p=0.007). Conclusion: In a community-based primary prevention cohort, 20% aged 55-77 were eligible for lung cancer screening CT. CMS eligibility criteria identified disease-free persons with substantially more incident hard CVD and CAC; CVD was more common than lung cancer. The results support cardiovascular prevention and reporting of CAC as part of routine lung cancer screening CT.
Does Glypican 3 expression in non-small cell lung cancer suggest an oncogenic function?
Authors: Sarit Aviel-Ronen, Melania Pintilie, Davina Lau, Serge Jothy, Ming-Sound Tsao
Journal: Cancer Research (2007)

187  Background: Glypican 3 (GPC3) is a membrane bound proteoglycan with peak expression during fetal life that is down-regulated after birth. Although GPC3 precise function is debated its expression is well linked with adult (hepatocellular carcinoma) and childhood malignancies (Wilm’s tumour, neuroblastoma) by both existence of mutations and aberrant protein expression. GPC3 expression pattern in non-small cell lung cancer (NSCLC) is still ambiguous with some evidence of loss of expression in NSCLC suggestive of a tumour suppressor role. The objective of this work was to evaluate GPC3 immunohistochemical (IHC) profile in NSCLC and correlate it with clinical and histological characteristics.  Methods: Our cohort contained 97 patients who underwent surgical resection of NSCLC and have been followed up for a median period of 4.81 years. IHC stain for GPC3 was performed on a tissue microarray constructed from respective samples and scored by two pathologists. GPC3 IHC stain association with clinical and histological parameters was evaluated.  Results: GPC3 stain was negative in all normal lung tissues but was positive in 22.7% of NSCLC, with statistically significant predilection for squamous cell carcinoma (SCC) compared to adenocarcinoma (ADC) (positive stain in 8% of ADC vs. 55% of SCC, p  Conclusion: In contradiction with previous report, we found GPC3 to be over expressed in NSCLC compared with normal tissue, especially in smokers and in SCC. These features are in agreement with known expression during normal development and suggest a possible oncogenic function, resembling GPC3 role in hepatocellular carcinoma.
Aberrant oligodendroglial–vascular interactions disrupt the blood–brain barrier, triggering CNS inflammation
Authors: Jianqin Niu, Hui-Hsin Tsai, Kimberly K. Hoi, Nanxin Huang, Guangdan Yu, Kicheol Kim, Sergio E. Baranzini, Lan Xiao, Jonah R. Chan, Stephen P. J. Fancy
Journal: Nature Neuroscience (2019)
THU-382-Use of facility-based provider initiated testing and counselling approach to ascertain viral hepatitis C status in high burden populations in Nigeria
Authors: Chukwuemeka Agwuocha, Jilian Sacks, Caroline Boeke, Ena Oru, Adamu Ibrahim, Namita Bansal, Justus Jiboye, Folu Lufadeju, Owens Wiwa
Journal: Journal of Hepatology (2019)
Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma
Authors: Justine V. Cohen, Ryan J. Sullivan
Journal: Clinical Cancer Research (2019)

The characterization of the MAPK signaling pathway has led to the development of multiple promising targeted therapy options for a subset of patients with metastatic melanoma. The combination of BRAF and MEK inhibitors represents an FDA-approved standard of care in patients with metastatic and resected BRAF-mutated melanoma. There are currently three FDA-approved BRAF/MEK inhibitor combinations for the treatment of patients with BRAF-mutated melanoma. Although there have been significant advances in the field of targeted therapy, further exploration of new targets within the MAPK pathway will strengthen therapeutic options for patients. Important clinical and translational research focuses on mechanisms of resistance, predictive biomarkers, and challenging patient populations such as those with brain metastases or resected melanoma.
Abstract 13610: Association Between Cardiovascular Health and Cognitive Performance: A Twins Study
Authors: Ambar Kulshreshtha, Alvaro Alonso, Amit J Shah, Viola Vaccarino, Douglas Bremner, Jack Goldberg
Journal: Circulation (2017)

Background and Objective: American Heart Association defined ideal cardiovascular health (CVH) across 7 modifiable risk factors for cardiovascular diseases and created targets by defining ideal levels for each factor. Prior studies have indicated that ideal CVH also benefits brain health and cognitive aging. It is unknown if this association is independent of genetic and early environment factors. Methods: We examined 272 male monozygotic(MZ) and dizygotic(DZ) twin pairs free of overt cardiovascular disease from the Vietnam Era Twin Registry. Memory and learning were measured by Trail making tests, Wechsler Memory Scale, and Verbal and Visual Selective Reminding Tests. CVH components were measured by medical history and laboratory testing. Each of the seven CVH components (smoking, body mass index, physical activity, diet, total cholesterol, blood pressure, and blood glucose) was given a point score of 0, 1 or 2 to represent poor, intermediate, or ideal health, respectively. The scores were then summed to...
Principles of Radiation Therapy
Journal: BMJ (1941)

This chapter provides a brief overview of the principles of radiation therapy. The topics to be discussed include the physical aspects of how radiation works (ionization, radiation interactions) and how it is delivered (treatment machines, treatment planning, and brachytherapy). Recent relevant techniques of radiation oncology, such as conformal and stereotactic radiation therapy, also will be presented. These topics are not covered in great tech­nical detail. It is hoped that a basic understanding of radiation treatment will benefit those practicing in other disciplines of cancer management. This chapter does not address the principles of radiobiology, which guide radiation oncologists in determining issues of treatment time, dose, and fractionation or in combining radiation with sensitizers, protectors, and chemotherapy or hormones.
THU-133-Resistance-guided retreatment of HCV infected patients with a previous failure to an NS5A inhibitor-containing regimen: Italian real life experience
Authors: Velia Chiara Di Maio, Marianna Aragri, Chiara Masetti, Stefania Paolucci, Bianca Bruzzone, Elisabetta Degasperi, Silvia Barbaliscia, Teresa Pollicino, Carmine Minichini, Vincenza Calvaruso, Maria Grazia Rendina, Valeria Cento, Elisabetta Teti, Valeria Micheli, Valeria Ghisetti, Ennio Polilli, Valeria Pace Palitti, Simona Landonio, Ilaria Lenci, Laura Donnarumma, Laura Ambra Nicolini, Ada Bertoli, Caterina Pasquazzi, Maria Paola Callegaro, Filomena Morisco, Giovanni Cenderrello, Simona Marenco, Roberto Gulminetti, Stefano Novati, Pietro Andreone, Alessia Ciancio, Vincenzo Sangiovanni, Nunzia Cuomo, Giulia Morsica, Vanni Borghi, Ivana Rita Maida, Maurizia Brunetto, Raffaele Cozzolongo, Adriano De Santis, Miriam Lichtner, Sergio Babudieri, Gloria Taliani, Teresa Santantonio, Claudio Paternoster, Roberto Ganga, Massimo Puoti, Giuliano Rizzardini, Adriano Pellicelli, Pietro Lampertico, Giustino Parruti, Coppola Nicola, Maurizio Zazzi, Giovanni Raimondo, Massimo Andreoni, Antonio Craxi, Angelico Mario, Carlo Federico Perno, Silberstein Francesca Ceccherini
Journal: Journal of Hepatology (2019)